EGFR and non-small cell lung carcinoma: The results of AURA3, a randomized phase III trial, indicated that osimertinib monotherapy had greater CNS efficacy than pemetrexed/platinum chemotherapy in treating EGFR T790M‐positive, TKI‐resistant NSCLC after prior TKI (median CNS PFS: 11.7 vs. 5.6 months, p = 0.004).45